PreludeDx™ to Present DCISionRTÒ and Novel Residual Risk Subtype Prospective Data During Scientific Oral Session at ASTRO 2022 Annual Meeting

/PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

Related Keywords

San Antonio ,Texas ,United States ,Australia ,Perth ,Western Australia ,Chirags Shah ,Dan Forche ,Andrew Wade ,Cory Dunn ,Yvonne Zissiadis Jr ,Instagram ,Linkedin ,Prnewswire Prelude Corporation Preludedx ,National Cancer Institute ,Prelude Corporation ,American Society For Radiation Oncology ,Taussig Cancer Institute ,Facebook ,University Of California San Francisco ,Department Of Radiation Oncology ,Henryb Gonzalez Convention Center ,Residual Risk Subtype ,Annual American Society ,Radiation Oncology ,Convention Center ,Re Thinking Clinicopathologic Risk Assessment ,Pooled Data ,Validation Studies Comparing ,Clinicopathologic Features ,Breast Radiation Oncology ,Cleveland Clinic ,Will Be Presented ,Prospective Registry ,Clinical Utility ,Biomarker Assay ,Treatment Decisions ,Breast Conserving ,Radiation Oncologist ,California San Francisco ,Decision Score ,Know Your Risk ,Fjord Ventures ,Investor Contact ,Preludedx ,